Multivariate data analysis and metabolic profiling of artemisinin and related compounds in high yielding varieties of Artemisia annua field-grown in Madagascar  by Suberu, John et al.
M
r
ﬁ
J
a
b
G
a
A
R
A
A
K
A
M
M
1
g
b
d
o
W
o
A
o
a
s
i
i
t
f
t
c
b
f
t
h
0Journal of Pharmaceutical and Biomedical Analysis 117 (2016) 522–531
Contents lists available at ScienceDirect
Journal  of  Pharmaceutical  and  Biomedical  Analysis
j o ur nal ho me  page: www.elsev ier .com/ lo cate / jpba
ultivariate  data  analysis  and  metabolic  proﬁling  of  artemisinin  and
elated  compounds  in  high  yielding  varieties  of  Artemisia  annua
eld-grown  in  Madagascar
ohn  Suberua,  Piotr  S.  Gromskib, Alison  Nordonb,  Alexei  Lapkina,∗
Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB2 3RA, UK
WestChem, Department of Pure and Applied Chemistry, and Centre for Process Analytics and Control Technology (CPACT), University of Strathclyde,
lasgow G1 1XL, UK
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 10 May  2015
a  b  s  t  r  a  c  t
An  improved  liquid  chromatography-tandem  mass  spectrometry  (LC–MS/MS)  protocol  for rapid  analy-
sis  of  co-metabolites  of A.  annua  in  raw  extracts  was  developed  and  extensively  characterized.  The newccepted 1 October 2015
vailable online 9 October 2015
eywords:
rtemisia annua
ultivariate data analysis
method  was  used  to analyse  metabolic  proﬁles  of  13 varieties  of  A. annua  from an  in-ﬁeld  growth  pro-
gramme  in  Madagascar.  Several  multivariate  data  analysis  techniques  consistently  show  the  association
of artemisinin  with  dihydroartemisinic  acid.  These  data  support  the  hypothesis  of dihydroartemisinic
acid  being  the  late  stage  precursor  to artemisinin  in  its biosynthetic  pathway.
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. Introduction
In 2013, there were an estimated 198 million cases of malaria
lobally, resulting in over half a million fatalities [1]. These num-
ers are a signiﬁcant improvement on the morbidity and mortality
ata from previous years [2–4] due, in part, to the effectiveness
f the artemisinin combination therapies (ACTs), backed by the
orld Health Organisation (WHO). ACT is used in the treatment
f uncomplicated P. falciparum malaria. The active ingredients of
CTs are derived from artemisinin (1), an endo-peroxide lactone
btained from Artemisia annua (A. annua) plant. Artemisinin is now
lso being produced semi-synthetically to improve the stability of
upply of this active pharmaceutical ingredient (API) [5].
However, the natural product route to artemisinin remains an
mportant part of the supply chain. To keep the plant route prof-
table necessitates the development of high-yielding plant cultivars
hrough selective breeding programmes. If bioreﬁning will in the
uture develop into industrial reality, it will offer additional oppor-
unities to increase the value of plant production, e.g. through
o-production of other valuable secondary metabolites that could
e converted to artemisinin, or used in the manufacture of other
unctional molecules of commercial interest [6]. Identifying poten-
ial target compound(s) in plant extracts will then need to take
∗ Corresponding author: Fax: +44 12234796
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731-7085/© 2015 The Authors. Published by Elsevier B.V. This is an open access article uinto account the biosynthesis of artemisinin, the concentration of
metabolites and the mechanism by which these precursors are con-
verted to artemisinin in planta.
Biosynthesis of artemisinin has been well studied and several
reviews on the topic are published [7–10]. Similar to all sesquiter-
penes, the synthesis involves condensation of 5-carbon molecules
from the mevalonate and the deoxy-d-xylulose-5-phosphate (DXP)
pathways to fernesyl pyrophoshate (IPP) as shown in Fig. 1. In A.
annua the mevalonate and the DXP pathways occur in cytosol and
plasmid, respectively. The committed step of the biosynthesis is the
cyclization of fernesyl diphosphate into amorpha-4,11-diene and
its subsequent conversion to artemisinin alcohol. The route from
artemisinin alcohol to artemisinin is still not entirely clear: pub-
lished data is inconclusive and sometimes contradictory [11,12].
The ﬁnal stages of artemisinin biosynthesis remain controversial
with conﬂicting theories identifying the last-stage precursor either
as dihydroartemisinic acid (4) or artemisinic acid (5). Li et al. [11]
has reviewed evidence for artemisinic acid, while Brown and oth-
ers [7,9,13,14] have done the same for dihydroartemisinic acid as
the key precursors Scheme 1.
In our previous studies we have investigated the variability of
metabolic proﬁles of A. annua grown in very different geographi-
cal regions and the impact of this variability on the extraction and
puriﬁcation of artemisinin [6]. For this we also developed a mass
spectrometry method for rapid evaluation of six key artemisinin-
related metabolites in raw extracts [15]. Based on the latter work
we were surprised to see a reproducibly high concentration of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
J. Suberu et al. / Journal of Pharmaceutical and Biomedical Analysis 117 (2016) 522–531 523
Fig. 1. Schematic of artemisinin biosynthetic pathway. DXS = 1-deoxy-d-xylulose-5-phosphate synthase, DXR = 1-deoxy-d-xylulose-5-phosphtae reductoisomerase,
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dDI  = IPP and DMAPP isomerase, HMGR = 3-hydroxy-3-methylglutaryl-CoA reducta
DCO  = Amorpha-4,11-diene C-12 oxydase, DBR2 = Double bond reductase 2, Aldh1
ihydroartemisinic acid, speciﬁcally in the biomasses proﬁled.
his coincided with an extensive programme of testing of the
mpact of growth conditions, mainly light and temperature, on
he production of artemisinin, undertaken in Madagascar. Based
n the available literature data for the biosynthetic pathway to
rtemisinin, a high concentration of dihydroartemisinic acid may
avour one of the two proposed routes [8]. The high concentra-
ion may  also offer a new biomass exploitation route through
ynthetic conversion of dihydroartemisinic acid into artemisinin
n a process similar to that developed by Seeberger [16]. Hence,
e decided to undertake an extensive study of key artemisinin-
elated metabolites in the Madagascar-grown A. annua biomass as
 function of growth stages and conditions. Attempts at studying
he evolution of artemisinic metabolites in A. annua plants grown
n glasshouses have been undertaken earlier [8,17,18]. This study
istinctly assesses the proﬁle of the ﬁeld-grown cultivarsDS = Amorpha-4,11-diene synthase, ADMO = Amorpha-4,11-diene monoxygenase,
hyde dehydrogenase 1, CYP = Cytochrome P450.
and evaluates possible biosynthetic associations among these
metabolites.
To aid in the identiﬁcation of associations between metabo-
lites and biosynthetic precursors, different methods of multivariate
data analysis have been used in the literature [8,19]. Numerous
multivariate methods, both supervised and unsupervised, have
been described in terms of reporting standards for metabolomics
studies [20–22]. However, it was recently shown that some meth-
ods e.g., partial least squares-discriminant analysis (PLS-DA) [23],
might lead to incorrect conclusions when used by inexperienced
researchers [24,25]. Therefore, in this study we employed prin-
cipal component analysis (PCA) [26], hierarchical cluster analysis
(HCA) [27] and discriminant function analysis (DFA) [28], since
these methods offer transparent outcomes. In addition, DFA in
comparison to PLS-DA requires fewer decisions about param-
eters that have to be optimized and, therefore, the model is
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Scheme 1. Chemical structures of m
ore directly related to the statistical properties of the data
24,25,29,30].
This paper reports the results of a detailed study of the evolu-
ion of key artemisinin-related metabolites for different A. annua
ultivars grown in Madagascar. It reports an improved liquid
hromatography-tandem mass spectrometry (LC–MS/MS) method
or these key metabolites and presents results of detailed multi-
ariate data analysis of the metabolite concentrations and growth
onditions.
. Experimental
.1. Chemicals
Artemisinin reference standard (98%), LC–MS grade formic acid
n water and acetonitrile, high-performance liquid chromatog-
aphy (HPLC) grade acetonitrile, ethyl acetate and hexane were
btained from Sigma–Aldrich (Dorset UK). Dihydroartemisinic acid
>96%) was purchased from Apin Chemicals (Oxfordshire, UK).
rteannuin B, artemisitene and artemisinic acid were kindly pro-
ided by Walter Reed Army Institute of Research (Washington
SA). Puriﬁed water (∼18 M cm−1) was dispensed from a Milli
 system (Millipore, UK).
.2. Analytical standards
Standard stock solutions of 1 mg  mL−1 of artemisinin (1),
rtemisitene (2), arteannuin B (3), artemisinic acid (4) and dihy-
roartemisinic acid (5) in acetonitrile were prepared. The analytical
tandard was a mixture of all ﬁve standards in a mobile phase in
he concentration range between 0.37–10 g mL−1 for (1), (2) and
3). For (4) and (5) -artemether was used as an internal standard
t 5 g mL−1.olites of interest found in A. annua.
2.3. Plant varieties
Thirteen varieties of A. annua plants from breeding pro-
grammes selecting for high artemisinin content were evaluated
for artemisinin and related metabolites levels to provide crosses
for new hybrids. These included four genotypes (CNAP1209R,
CNAP5013, CNAP8001R, CNAP1252R) from the breeding pro-
gramme  of the Centre for Novel Agricultural Products (CNAP,
York, UK). Another six (NIAB1125, NIAB1129, NIAB1105, NIAB1114,
NIAB1118, NIAB1131) were from the National Institute of Agricul-
tural Biology (NIAB, Cambridge, UK), and one cultivar (KEF1) from
Kenya. These were benchmarked against the Apollon and NIAB1062
genotypes from Médiplant and NIAB respectively. Laurus nobilis
(bay laurel) was used as a negative control and plant matrix for
the assessment of the matrix effect.
2.4. Sampling period
Sampling for metabolic proﬁling commenced at 90 days post
transplantation and samples were taken every fourth night up to
161 days. This window coincided with the period of quantiﬁable
concentrations of all the targeted metabolites in the plant from ear-
lier observations. Little or no ﬂowering occurs in the plant during
the winter season when these were grown, consequently corre-
sponding to the vegetative and bolting stages of the plant.
2.5. Sample extraction and preparation
Extraction of dried plant leaves was carried out using published
protocols [15,31,32]. Brieﬂy, 0.5 g of the biomass was extracted with
10 mL  of hexane modiﬁed with 5% (v/v) ethyl acetate in an ultra-
sonic bath (Kerry, Ultrasonics, UK), which was  kept cold with ice;
the extraction duration was  always 30 min. The extracts were dried
in vacuo and the residue re-suspended in acetonitrile before ﬁlter-
ing through a 0.2 m Nylon syringe ﬁlter (Fisher Scientiﬁc, UK). An
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Table  1
TQD parameters for MS/MS  experiments.
Cone voltage (V) Collision voltage (V) MRM  transitions
Artemisinin (1) 24 7 283 → 219 + 229 + 247 + 265
Artemisitene (2) 30 10 281 → 217 + 227 + 245 + 263
Arteannuin B (3) 28 9 249 → 189.5 + 213.5 + 221.5 + 231.5
Dihydroartemisinic acid (4) 32 12 237 → 191 + 201 + 219
a
p
a
w
2
2
S
q
T
a
a
(
T
0
a
9
0
2
i
T
8
a
4
m
a
s
i
a
D
c
2
s
v
n
t
b
e
t
e
t
2
H
w
pArtemisinic acid (5) 32 
liquot of the ﬁltrate was diluted in the mobile phase to an appro-
riate concentration and the internal standard added for LC–MS
nalysis. L. nobilis (bay laurel), which was used as a negative control,
as extracted using the same procedure.
.6. Plant metabolites analysis
.6.1. Liquid chromatography method
The liquid chromatography analyses were performed using a
himadzu Prominence HPLC system coupled to a Xevo tandem
uadrupole mass spectrometer (Waters Corp., Milford, MA,  USA).
he Shimadzu system consisted of a binary pump, an auto-sampler,
 UV detector and a column oven. The column heater was set
t 30 ◦C and a Cortecs C18 column (100 mm × 2.1 mm,  2.7 m)
Waters Corp., USA) was used for separation of the metabolites.
he mobile phase consisted of A: 0.1% formic acid in water and B:
.1% formic acid in acetonitrile. Chromatographic separation was
chieved using a linear gradient: 0–7.0 min, 25–98% B; 7–9.5 min,
8% B; 9.5–10 min, 98–25% B; 10–15 min, 25% B; at a ﬂow rate of
.4 mL  min−1.
.6.2. Multiple reaction monitoring (MRM)  method
The tandem MS  experiments were carried out in positive ion-
zation mode (ESI+) and acquisition was performed in MRM  mode.
he cone and de-solvation gas ﬂow rates were set at 45 and
00 L h−1, respectively, while the capillary voltage, the source
nd de-solvation temperatures were similar for all analytes at
0 kV, 150 and 350 ◦C respectively. The MS  parameters were auto-
atically deﬁned using Waters IntelliStart® software for tuning
nd calibration of the tandem quadrupole detector (TQD) and
ubsequently was manually optimized. Final parameters are shown
n Table 1 Quantiﬁcation was achieved using MRM  modes for the
bove transitions. The dwell time was automatically set at 0.161 s.
ata were acquired by MassLynx v. 4.1 and processed for quantiﬁ-
ation with QuanLynx v. 4.1 (Waters Corp., Milford, MA,  USA).
.7. Multivariate data analysis
All statistical data analyses were conducted using the R (v. 3.1.0)
oftware environment (http://cran.r-project.org/). Two  unsuper-
ised algorithms were used to reveal hidden structure in the data,
amely PCA and HCA. These methods allow identiﬁcation of rela-
ionships among different data points (i.e. samples) as well as
etween different variables, in this case metabolites [26,27]. How-
ver, both techniques only permit analysis of the data according
o its features, i.e. without class labels and, therefore, DFA was
mployed to discover the patterns, which will link the inputs with
he output [28].
.8. Data pre-processingIn this study, samples were analysed using LC coupled to MS.
owever, this method provides data that are often incomplete,
hich may  be related to a number of reasons, such as com-
lex deconvolution, measurement error, detection sensitivity and12 235 → 190 + 200 + 218
many more [33]. Therefore, pre-processing methods/strategies
were employed to make the data more clear and suitable for
analysis. In the ﬁrst stage, all the missing values were replaced
using random forests [33]. This method was selected over
other approaches as this technique provides more robust and
accurate results as recently shown [33]. Once all missing values
were imputed, the data were auto-scaled to transform all the vari-
ables to one comparable scale [34].
3. Results and discussion
3.1. Chromatography
An earlier published method for the analysis of artemisinin,
artemisitene artemisinic acid and arteannuin B was used as a start-
ing point [15]. The level of dihydroartemisinic acid (DHAA) reported
by this method is higher than that reported by other investiga-
tors [35–37]. This discrepancy informed a revisiting of our DHAA
method [15] and investigation of why  elevated readings for the
metabolite were obtained earlier. Consequently we suspected that
the transitions (237 → 190 + 200 + 218) chosen for the analysis of
dihydroartemisinic acid in the earlier method [15] may  be speciﬁc
not only to dihydroartemisinic acid alone but may be susceptible
to interference from very closely related compounds in the extract.
Our attempt at the identiﬁcation of these related metabolites is
ongoing, while here we undertook to correct this error and develop
a more robust method speciﬁc for dihydroartemisinic acid alone.
3.1.1. Method validation—dihydroartemisinic acid
The International Conference on Harmonization (ICH) [38]
guideline for bio-analytical method validation were employed for
the deﬁnition and determination of recovery speciﬁcity, precision,
limits of detection and quantiﬁcation and analytical range of the
method.
3.1.2. Recovery
Eight equal portions (0.5 g) of one of the (CNAP) samples were
used to assess the recovery of the metabolites from the extract.
Three of the extracts were spiked with dihydroartemisinic acid
(4) to give a ﬁnal concentration of 4.10 g mL−1. The remaining
ﬁve extracts were un-spiked. Table 2 shows that a recovery of
between 97.56–108.05 % and a mean of 104.31% was obtained for
the metabolite.
3.1.3. Speciﬁcity
Fig. 2A shows the fragmentation proﬁle of dihydroartemisinic
acid from a tandem MS  scan. The MRM  transitions selected for
dihydroartemisinic acid are shown in Fig. 2B. Our non-selection
of the comparatively stronger 237 > 163 m/z was informed by the
reduced speciﬁcity associated with the lower m/z  relative to higher
ones. The intensities of the chosen transitions were adequate, see
Fig. 2B and were used for the qualitative tandem (MS/MS) exper-
iment to identify the metabolite. The total ion current (TIC) data
was obtained from the sum of the m/z intensities of each of the
transitions monitored while the transition with the relatively high-
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Fig. 2. (A) Fragmentation pattern for dihydroartemisinic acid. (B) Chosen MRM  transitions for dihydroartemisinic acid.
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st signal intensity (237 > 219) of the chosen ions was used in the
uantitative analysis.
Speciﬁcity of MS/MS  experiments is inherent; however fur-
her comparative analysis of two samples of equal concentration
f DHAA (5 g mL−1), one sample spiked with closely related
etabolites (artemisinin (1), artemisitene (2), arteannuin B (3) and
rtemisinic acid (5), each at 5 g mL−1) and the other un-spiked
as carried out. Both samples showed only dihydroartemisinic acid
eak in the MRM  experiment for the metabolite and a mean con-
entration of 5.03 ± 0.03 g mL−1 was obtained.d metabolites analysed in this study.
3.1.4. Limit of detection (LOD), lower limit of quantiﬁcation
(LLOQ) and dynamic range
The limit of detection is deﬁned as the lowest amount of analyte
in a sample, which can be detected but not necessarily quantitated,
while the lower quantiﬁcation limit is the lowest amount of analyte
in a sample, which can be quantitatively determined with suit-
able precision and accuracy. The standard calibration curve was
used to calculate these limits following Miller and Miller [39]. The
LOD and LLOQ for the metabolite were determined to be 0.12 and
0.37 g mL−1 respectively, see Table 2.
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Table  2
Recovery, LOD, LLOQ, precision and matrix effect.
Recovery
Mean quantity in
un-spiked samplea
(g mL−1)
Spiked quantityb (g mL−1) Total quantity in spiked
samplec (g mL−1)
Recovered quantities
(g mL−1)
Spiked sample 1d 0.60 ± 0.06 4.10 ± 0.05 4.60 ± 0.17 4.00 ± 0.12 (97.56%)
Spikes  sample 2d 0.87 ± 0.07 4.10 ± 0.05 5.30 ± 0.10 4.43 ± 0.20 (108.05%)
Spiked  sample 3d 1.47 ± 0.12 4.10 ± 0.05 5.87 ± 0.43 4.40 ± 0.55 (107.32%)
Mean  + standard error 4.28 ± 0.14 (104.31%)
LOD,  LLOQ and precision
LODe = 1.24 × 10−1 (g
mL−1)
LLOQe = 3.72 × 10−1
(g mL−1)
Regression equation y = 59747x + 25816
Precision (%) Mean Range Coefﬁcient of variance (CV)
Injectionf 102.46 98.36–106.56 (n = 10) 4.22
Within-dayg 104.72 95.85–112.00 (n = 12) 8.02
Between-dayg 103.37 90.00–116.00 (n = 48) 8.80
Ion  suppression (matrix effect)
Spiked plant matrix
(g mL−1)h
Spiked blank matrix (g mL−1)i
Sample 1 Sample 2 Sample 3
Mean  3.32 3.54 (+2.79%) 3.38 (+0.33%) 3.45 (+1.07%)
Standard error (SE) 0.02 0.07 0.01 0.03
Eight equal samples of 0.5 g of dried A annua leaves (CNAP variety) were extracted and prepared for analysis. aFive of these extracts were un-spiked while three were spiked
at  indicated levelsb. The total quantityc of analyte in the samples was  calculated as the sum of the mean quantities in ﬁve un-spiked samples and the spiked quantity.
Analyte levels in individual spiked samples were determinedd and absolute and percentage recoveries presented (in bracket). eLOD and LLQD calculations were based on
10  point calibration graph and the following formulae LOD = YB + 3SB and LLQD = 3LOD, where YB is the blank signal (the y—intercept) and the SB is the standard deviation
of  the blank (the random error in the y-direction) [39]. fInjection precision was  assessed by n determinations at 100% concentration. gWithin and between-day precision
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ercentage enhancement is shown in brackets.
The linearity of the calibration curve was above r2 > 0.99 in
oth the mobile phase and the mobile phase spiked with the
atrix. The regression and sensitivity indices presented in Table 2
ere obtained for the standards prepared in the mobile phase
piked with plant matrix. The method’s dynamic range was
.12–10 g mL−1.
.1.5. Precision
The precision parameters for the method are shown in Table 2.
he injection precision was assessed from 10 determinations of the
etabolite at 100% of the concentration in the analytical sample in a
ingle day. The coefﬁcient of variation (CV) for these determinations
as found to be adequate (4.2%).
Within day precision was determined for 6 concentration levels
overing the analyte calibration range, making a total of 12 analyses
n a single day. Between days accuracy was calculated for the same
alibration range spread over 3 months, resulting in a total of 48
eterminations. An accuracy range of 90.00–116.00% was  obtained
or both within and between day determinations and the coefﬁcient
f variance was less than 9.0% in both analyses.
.1.6. Ion suppression and matrix effect
The suppression or enhancement of ionization due to the pres-
nce of endogenous components in the plant matrix may  occur in
C–MS or LC–MS/MS based assays with consequential impact on
he precision and accuracy of the bio-analytical method [40]. Dif-
erent strategies have been used for the assessment of the matrix
ffect [41,42], including the spike method that was used in our
etermination. The strategy involves comparing the response of the
etabolite in the plant matrix to the response in the blank matrix
mobile phase), both matrices spiked with an equivalent concentra-
ion of the metabolite and treated through the sample preparation
rotocol [43].
The three samples of dihydroartemisinic acid spiked with plant
atrix Table 2 showed minimal ion enhancement (0.33–2.79%)isions. hMean of three determinations of spiked standards at 3.32 mg mL −1. iThree
5:25) spiked with standard at an equivalent concentration to spiked plant matrix.
compared with the metabolites solubilised in the blank matrix
(mobile phase).
The above validation indices showed the method to be robust
and sensitive for the analysis of dihydroartemisinic acid in crude
extracts. The levels of the metabolite detected by this method
is consistent with that reported by Larson et al., citing a higher
artemisinin content relative to dihydroartemisinic acid for most
of the commercially grown lines they evaluated [17]. This is in
contrast to the previous protocol [15] that found higher concen-
trations of dihydroartemisinic acid relative to artemisinin in the
analysed biomasses. Accumulation of secondary metabolites in
plants depends on various factors including, among others, stage
and condition of growth. The assessment of the evolutionary trend
for some artemisinic metabolites in A. annua by both Wang et al.
[8] and Towler and Weathers [18] showed a lower accumulation of
dihydroartemisinic acid relative to artemisinin at the later vegeta-
tive stage of the plant, this stage, coincided with our sampling. They
also observed, that the trend was  reversed at the early vegetative
stages.
3.2. Heat map and metabolite proﬁle
The metabolic proﬁle of artemisinin related compounds over the
growing period of the experimental plants is visualized as a heat-
map  in Fig. 3. The map  is colour-coded to three levels of metabolite
expression (blue = low range, yellow = middle range, brown = high
range). The categorisation is based on the determined range of the
metabolite content found in all the samples analysed.
The NIAB samples showed very close similarity in their
artemisinic acid, artemisitene and arteannuin B content. The lev-
els of these metabolites do not change signiﬁcantly over the
growth period compared to other cultivars sampled, and are all
detected at the comparatively low concentration range for these
metabolites. The CNAP samples showed comparatively more vari-
ation among cultivars with signiﬁcant increases in the content
of these metabolites detected over the sampled growth period in
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Table 3
Content of artemisinin and related metabolites at the end of sampling.
Plant cultivar Artemisinin/mg g−1 Dihydroartemisinic acid/mg g−1 Artemisinic acid/mg g−1 Artemisitene/g g−1 Arteannuin B/g  g−1
1 V1-CNAP1209R 8.47 ± 0.51 4.95 ± 0.60 0.71 ± 0.04 2.63 ± 0.13 65.23 ± 0.52
2  V2-CNAP5013 11.48 ± 0.28 4.98 ± 0.51 1.17 ± 0.07 9.80 ± 1.37 103.62 ± 4.50
3  V3-CNAP8001R 13.01 ± 0.08 5.01 ± 0.54 1.46 ± 0.08 13.47 ± 0.63 146.83 ± 11.25
4  V4-CNAP1252R 12.71 ± 0.44 4.92 ± 0.61 0.45 ± 0.05 4.94 ± 0.57 40.23 ± 4.12
5  V5-KF1 12.21 ± 0.88 4.86 ± 0.40 1.65 ± 0.13 6.84 ± 0.44 159.97 ± 10.47
6  V6-NIAB1125 10.80 ± 0.26 4.74 ± 0.49 0.53 ± 0.03 4.31 ± 0.46 34.45 ± 2.03
7  V7-NIAB1129 11.10 ± 0.30 3.73 ± 0.49 0.41 ± -0.03 3.93 ± 0.69 37.22 ± 4.03
8  V8-NIAB1105 11.07 ± 0.26 5.35 ± 0.41 0.58 ± 0.02 2.45 ± 0.26 49.67 ± 1.40
9  V9-NIAB1114 10.04 ± 0.51 4.05 ± 0.69 0.42 ± 0.02 2.84 ± 0.12 45.21 ± 1.45
10  V10-NIAB1118 11.27 ± 0.12 7.36 ± 0.11 0.60 ± 0.02 3.87 ± 0.04 32.47 ± 4.21
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p11  V11-NIAB1131 10.40 ± 0.65 5.08 ± 0.38 
12  T1-APOLLON 10.91 ± 0.15 4.67 ± 0.28 
13  T2-NIAB1062 10.48 ± 0.28 4.80 ± 0.48 
ome of the cultivars. This is also true for the Apollon and Kenyan
ultivars sampled, see Fig. 3.
The artemisinin and dihydroartemisinic acid content of the sam-
led cultivars increased over the growth period in all of the varieties
ith the exception of one CNAP cultivar (CNAP8001R), which had
igh levels of DHAA at the beginning and end of sampling.
The heat maps for artemisinic acid, artemisitene and arteannuin
 are generally similar for these metabolites in the analysed sam-
les. The artemisinin and dihydroartemisinic acid maps are more
istinct from the other metabolites and these distinctions seem
o correlate with the result of the principal component analysis
elow.
.3. Metabolic proﬁle and biosynthetic association
Table 3 shows the metabolic proﬁles of sampled culti-
ars at the end of the sampling period. For this period, the
ighest accumulation of artemisinin (13.01 ± 0.08 mg  g−1),
ihydroartemisinic acid (7.36 ± 0.11 m g−1), artemisinic acid
1.81 ± 0.06 mg  g−1), artemisitene (13.47 ± 0.63 g g−1) and
rteannuin B (171.32 ± 7.45 g g−1), occurred in CNAP8001,
IAB1118, Apollon, CNAP8001 and NIAB1118, respectively.
verall CNAP8001 had the best proﬁle for the metabolites
nalysed.
The comparatively higher level of accumulation of dihy-
roartemisinic acid relative to artemisinic acid in these cultivars
s consistent with the observation by Wallaart et al., who  showed
hat a higher accumulation of dihydroartemisinic acid was accom-
anied by higher artemisinin content, while a negative correlation
xisted between accumulation of artemisinic acid and artemisinin
14].
In the 13 cultivars examined, artemisinin is accumulated at
 level of between 2 and 3 (2.4 ± 0.08) times the levels of
ihydroartemisinic acid, except in two cultivars (NIAB1118 = 1.5
nd CNAP1209 = 1.7 times). Interestingly, a similar consistency
as observed in the relative accumulation of artemisinic acid
nd arteannuin B, which was between 10–12 (10.9 ± 0.20) times
expect in NIAB1118 = 18 and NIAB1125 = 15 times). This con-
istency was not observed in any other coupling and may
urther suggest an association between artemisinin and dihy-
roartemisinic acid in the biosynthetic pathways of our sampled
enotypes, while artemisinic acid seems to be associated with
rteannuin B in these cultivars.
Some investigators [44,45], have proposed arteannuin B as the
ntermediate in the pathway from artemisinic acid to artemisinin.
owever, Brown and Sy in their in vivo feeding experiments with
rtemisinic acid labeled with both heavy carbon (13C) and proton
2H), excluded it as precursor in biosynthesis of artemisinin in
. annua, but showed dihydroartemisinic acid as the late stage
recursor of artemisinin [46].0.39 ± 0.01 3.08 ± 0.35 33.80 ± 3.95
1.81 ± 0.06 10.97 ± 0.79 171.32 ± 7.45
0.58 ± 0.04 2.63 ± 0.45 48.35 ± 2.55
3.4. Principal component analysis
A total of 388 metabolite proﬁles obtained from 13 A. annua cul-
tivars were evaluated by PCA. These sets of data were divided into
ﬁve distinct groups, corresponding to the stages of growth sampled.
Each group comprises an average of 77 samples. Fig. 4A is the scores
plot of samples which show metabolite clustering based on stages
of growth. The relationships between monitored metabolites are
shown in Fig. 4B. Close association is observed for artemisinic acid
and arteannuin B with artemisitene the next associated to these
two.
3.5. Hierarchical cluster analysis
HCA was conducted using function “hclust” in R’s “stats” pack-
age in order to indicate relationship between the metabolites
investigated and to conﬁrm our ﬁndings relating to the corre-
lated variables as investigated using PCA. This is a frequently used
method that allows identiﬁcation of similarities/dissimilarities
between different individuals or correlations between different
variables, here—metabolites. The algorithm calculates a distance
matrix for a given data set using the “Euclidean distance”. As long
as the distance between any observations is calculated, the “Ward”
linkage is used to link different elements into clusters [27]. The out-
put of the hierarchical clustering computations is represented as a
tree-structured graph called a dendrogram. The hierarchical struc-
ture can either depict the assemblage for observations according
to their characteristics or display correlations between features,
i.e. metabolites, as calculated using correlation coefﬁcients. Con-
sequently, the variables with a short in-between distance are
expected to be similar or related.
The results of HCA for the metabolites are shown in Fig. 5,
where the dendrogram can be divided into two  subgroups: the
ﬁrst group contains arteannuin B which is highly correlated with
artemisinic acid followed by artemisitene and in the second group,
dihydroartemisinic acid and artemisinin, shows a much smaller
correlation in comparison to the ﬁrst group. The results of the clus-
ter analysis conﬁrm what has been observed when looking at the
loadings plot, Fig. 4B, i.e.  that two  subgroups of related metabolites
can be detected.
3.6. Discriminant function analysis
PCA is not always capable of satisfactorily separating the varia-
tions produced by each factor. This can be related to the fact that
the variations caused by these factors are spread across a different
number of components, which makes the results somewhat prob-
lematic to read. Therefore, in Fig. 4A some overlapping could be
observed. In order to circumvent this scenario supervised methods
can be applied to make the results clearer. One of the frequently
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Fig. 4. Results of PCA. (A) The scores plot showing samples clustered according to different stages of growth. (B) A loadings plot displaying relationships between different
variables, in this case the metabolites of interest.
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sed methods to reveal the structure in data with known labeling
s DFA. This technique applies Fisher’s ratio so as to search for a lin-
ar combination of factors that minimizes within group variance
nd maximizes between group variance [28]. This allows for allo-
ation of objects into groups, such that objects in the same group
re related.
The scores plot of DFA, see Fig. 6, indicates that the algorithm
as able to clearly separate samples related to different stages of
lant growth. In addition, the grouping is mostly related to the
evels of artemisinin, the metabolite that was recognized as an
nﬂuential factor using both unsupervised approaches (PCA and
CA). The level of artemisinin strongly depends on the growth
tage, with the highest levels observed in the last stage.
Overall, the combined use of these advanced multivariate tools
o study the evolution of artemisinic metabolites showed two
istinct sub-groupings of the metabolites. Artemisinin and dihy-
roartemisinic were clearly associated, and there was a correlation
or artemisinic acid, arteannuin B and artemisitene. The close prox-
mity of artemisinic acid and arteannuin B, and to a lesser extent for
rtemisinin and dihydroartemisinic acid on the dendogram along
ith the consistency of their relative accumulation in the analysedamples Table 3, supports the direct link between these metabo-
ites in the biosynthetic pathway Fig. 1. Higher accumulation of
rtemisinin has also been associated with lower concentrations of
rteannuin B and artemisinic acid and vise versa [8,47]. Our ﬁndings representing ﬁve different metabolites.
strengthen the suggestion of different chemotypes in A. annua: at
least one of high artemisinin and low artemisinic acid content and
the other of low artemisinin and high artemisinic acid levels [8,47].
Consequently, with carbon ﬂow directed at these two  alternative
or competing paths in the later stage of the biosynthetic process,
a key to the favoured direction of carbon ﬂow may  be the double
bond reductase 2 (DBR2) enzyme which catalyses the reduction
of artemisinic aldehyde to dihydroartemisinic aldehyde for subse-
quent conversion to dihydroartemisinic acid. Targeted study of the
enzyme in the different chemo-types could be advantageous.
4. Conclusions
In this study 13 genotypes were screened from three breeding
programs for superior artemisinin related metabolic proﬁles using
an earlier published and updated LC–MS protocols. Generally, all
evaluated validation indices showed the new analytical method to
be robust and sensitive for the analysis of the metabolites in crude
extracts.
The data set obtained from the metabolic proﬁling of the geno-
types was subjected to multivariate analysis to identify association
and correlation among metabolites. The PCA loadings plot and the
dendrogram shows two  distinct grouping among the ﬁve metabo-
lites analysed. Artemisinic acid and arteannuin B were found to be
more closely related than any of the metabolites, with artemisitene
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